Reuters logo
BRIEF-Cytrx highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissions
October 12, 2017 / 1:47 PM / 2 months ago

BRIEF-Cytrx highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissions

Oct 12 (Reuters) - Cytrx Corp:

* Cytrx Corporation highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissions planned by Licensee Nantcell, Inc. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below